Novo Nordisk’s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus


Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes.  The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD).
Additionally, Novo Nordisk presented phase 2 data which demonstrate insulin degludec’s potential to achieve glycemic control when used once-daily or three times weekly in people with type 2 diabetes.

For the full press release click here.

Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x